The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
Abstract
Avoidance of apoptosis is critical for the development and sustained growth of tumours. The pro-survival protein myeloid cell leukemia 1 (MCL1) is overexpressed in many cancers, but the development of small molecules targeting this protein that are amenable for clinical testing has been challenging. Here we describe S63845, a small molecule that specifically binds with high affinity to the BH3-binding groove of MCL1. Our mechanistic studies demonstrate that S63845 potently kills MCL1-dependent cancer cells, including multiple myeloma, leukaemia and lymphoma cells, by activating the BAX/BAK-dependent mitochondrial apoptotic pathway. In vivo, S63845 shows potent anti-tumour activity with an acceptable safety margin as a single agent in several cancers. Moreover, MCL1 inhibition, either alone or in combination with other anti-cancer drugs, proved effective against several solid cancer-derived cell lines. These results point towards MCL1 as a target for the treatment of a wide range of tumours.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Prior studies have demonstrated that sensitivity of cancer cells to MCL-1 inhibition is inversely related to BCL-XL expression level and the capacity for BCL-XL to neutralize pro-apoptotic BH3 proteins such as BIM60,61.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [60]
In the citing paper
“Conversely, the BCL2 inhibitor venetoclax is currently available for the treatment of CLL patients who fail to obtain clinical benefit from conventional therapies [1046], and several other molecules with a similar mechanism of action are currently in clinical development [118] (source https://clinicaltrials.gov/).”
From Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. (2018) · cites this paper as [118]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,796
MOLREP : an Automated Program for Molecular Replacement
Vagin, A. A., & Teplyakov, A. (1997) · Journal of Applied Crystallography · doi:10.1107/s0021889897006766 · Cited by 4,756
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,407
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
Czabotar, P. E., Lessene, G., Strasser, A., & Adams, J. M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3722 · Cited by 3,219
Self-citationABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058
Self-citationTargeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Roberts, A. W., Davids, M. S., Pagel, J. M., Kahl, B. S., Puvvada, S. D., Gerecitano, J. F., Kipps, T. J., Anderson, M. A., Brown, J. R., Gressick, L. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1513257 · Cited by 1,930
Self-citationChen, L., Willis, S. N., Wei, A., Smith, B. J., Fletcher, J. I., Hinds, M. G., Colman, P. M., Day, C. L., Adams, J. M., & Huang, D. C. S. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.12.030 · Cited by 1,816
Self-citation
Cited by
Sorted by citations
Items 801–900 of 1,001
Paysant, H., Hedir, S., Justaud, F., Weiswald, L., Dine, A. N. E., Soulieman, A., Hachem, A., Elie, N., Brotin, É., Denoyelle, C., et al. (2021) · Organic & Biomolecular Chemistry · doi:10.1039/d1ob01521d · Cited by 4
Odinius, T. O., Buschhorn, L., Wagner, C. V., Hauch, R. T., Dill, V., Dechant, M., Buck, M. C., Shoumariyeh, K., Moog, P., Schwaab, J., et al. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03827-9 · Cited by 4
Wang, A.-M., Qiu, R., Zhang, D., & Zhao, X. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101288 · Cited by 4
Smith, W., & Reed, D. R. (2022) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-022-00661-9 · Cited by 4
Pharmacological modulation of cell death in organ transplantation
Cippà, P. E., & Fehr, T. H. (2017) · Transplant International · doi:10.1111/tri.12977 · Cited by 6
Characterizing and Targeting of BCL ‐2 Family Members in Nasopharyngeal Carcinoma
Thai, A. A., Young, R. J., Bressel, M., Kelly, G. L., Sejic, N., Tsao, S. W., Trigos, A., Rischin, D., & Solomon, B. (2024) · Head & Neck · doi:10.1002/hed.27973 · Cited by 3
Self-citationCellular Senescence in Cancer: Mechanisms, Roles in Tumor Progression, and Therapeutic Implications
Yan, J., Zhang, Y., Mao, G., Yu, J., Zhou, T., & Hao, J. (2025) · MedComm – Oncology · doi:10.1002/mog2.70029 · Cited by 3
Hornsby, B. D., Tuekpe, J. K. K., Steele, C. A., Devereaux, A. A., Bowman, K. E. R., & Lim, C. S. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00773 · Cited by 3
Saga of MCL1 inhibitors in multiple myeloma
Nelson, E., Telang, S. P., Budak-Alpdoǧan, T., Jonnalagadda, S. C., Srivastava, S. K., & Pandey, M. K. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117532 · Cited by 3
CDK9 is a dependency in GATA-3 driven and MCL-1 independent T-cell Lymphomas
Wang, C., Abdelrahman, S., Geng, X., Burgess, A., Hu, Y., Rauf, M. A., Kady, N., Fu, Y., Reilly, T. A., Maine, I. P., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01427-1 · Cited by 3
Fleischmann, M., Hansen, O., Voigtländer, D., Bechwar, J., Schwietzer, L., Bahr, S., Schnetzke, U., Fischer, M., Heidel, F. H., Schnoeder, T. M., et al. (2026) · British Journal of Haematology · doi:10.1111/bjh.70344 · Cited by 3
BAK and BAX form a multiprotein complex to drive mtDNA efflux and caspase-independent cell death
Yang, S., Kim, H., Liao, G., Ta, N., Tu, H.-C., Ramani, S., Chen, C.-Y., Li, Z.-Y., Tanno, N., Hsieh, J. J.-D., et al. (2026) · Science · doi:10.1126/science.aea2181 · Cited by 3
New insights into binding of natural chalcones to Bcl-2, Bcl-xL and Mcl-1 anti-apoptotic proteins
Ćirin, D. M., & Krstonosic, V. S. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.130700 · Cited by 3
Mechanistic paradigms of cell death - revisited
Rana, S. V. S. (2021) · Journal of Environmental Biology · doi:10.22438/jeb/42/4/mrn-1965 · Cited by 3
Dunham, D., Viswanathan, P., Gill, J., & Manzano, M. (2022) · Journal of Virology · doi:10.1128/jvi.01360-22 · Cited by 3
Bong, A. H. L., Robitaille, M., Lin, S., Reed, A. E. M., Milevskiy, M. J. G., Angers, S., Roberts‐Thomson, S. J., & Monteith, G. R. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02183-0 · Cited by 3
Li, D., López, A., Shrivastava, N., Chan, W., Thomas, C., Burk, R. D., Segall, J. E., Augustine, S., Rosenblatt, G., Mehta, V., et al. (2024) · Oral Oncology · doi:10.1016/j.oraloncology.2024.107069 · Cited by 3
Ureshino, H., Ueshima, T., Yamaguchi, T., Takashima, M., Sanuki, Y., & Ichinohe, T. (2025) · Scientific Reports · doi:10.1038/s41598-025-98534-7 · Cited by 3
Mughees, M., Tacam, M. J., Tan, A. W., Pitner, M. K., Iles, L. R., Hu, X., Villodre, E. S., Debeb, B. G., Kogawa, T., Lim, B., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0593 · Cited by 3
Kump, K. J., Ahmad, E., Foucar, C. E., Avelar, R. A., Murga‐Zamalloa, C., Lieberman, M. L., Kandarpa, M., Mady, A. S. A., DiFeo, A. V., Zhang, L., et al. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00088 · Cited by 3
Chen, H., Yan, Z., Xiao, C., Tang, Z., & Wan, Y. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118079 · Cited by 5
miR-125b-5p Suppresses Leukemia Cell Proliferation by Regulating MCL1
Zhou, Y., Zhu, H., Han, J., Xu, Y., Wang, D., Jin, W., Zhu, R., & Qiao, L. (2022) · Journal of Environmental Pathology Toxicology and Oncology · doi:10.1615/jenvironpatholtoxicoloncol.2022041924 · Cited by 3
Sumarni, U., Zhu, J., Sinnberg, T. W., & Eberle, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012471 · Cited by 3
AKT inhibition sensitizes acute leukemia cells to S63845-induced apoptosis
Li, Y., Du, L., Ye, K., Sun, X. G., Hu, L., Gao, S., & Dai, H. (2023) · Hematology · doi:10.1080/16078454.2023.2214465 · Cited by 3
Acton, A., & Placzek, W. J. (2023) · Cancers · doi:10.3390/cancers15184481 · Cited by 3
Matsui, Y., Yamada, T., Katayama, Y., Hirai, S., Sawada, R., Tachibana, Y., Ishida, M., Kawachi, H., Nakamura, R., Nishioka, N., et al. (2024) · Cancer Science · doi:10.1111/cas.16292 · Cited by 3
Jin, W., Deng, Y., Marca, J. E. L., Lelliott, E. J., Diepstraten, S. T., Koenig, C., Tai, L., Snetkova, V., Dorighi, K. M., Hoberecht, L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56282-2 · Cited by 4
Self-citationTargeting mitotic exit in solid tumors.
Greil, C., Felthaus, J., Follo, M., Ihorst, G., Ewerth, D., Schüler, J. B., Schnerch, D., Duyster, J., Engelhardt, M. M., & Wäsch, R. (2021) · PubMed · Cited by 3
Loss of TRP53 reduces but does not overcome dependency of lymphoma cells on MCL-1
Aubrey, B. J., Brennan, M. S., Diepstraten, S. T., Wang, Z., Chang, C. W. T., Herold, M. J., Strasser, A., & Kelly, G. L. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-00946-9 · Cited by 3
Self-citationBrumatti, G., Lalaoui, N., Wei, A. H., & Silke, J. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.01.005 · Cited by 3
Self-citationCharacterization of a novel human BFL-1-specific monoclonal antibody
Gangoda, L., Teh, C. E., Dengler, M. A., Best, S. A., Weeden, C. E., Tai, L., Lee, E. F., Fairlie, W. D., Sutherland, K. D., Harrison, L. C., et al. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-019-0454-y · Cited by 3
Self-citationCo-expression of Mcl-1 and Bak induces mitochondrial swelling
Wang, Y., Su, W., Mai, Z., Du, M., Si, Y., Liu, Y., Wang, X., & Chen, T. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.04.154 · Cited by 3
Removal of BFL-1 sensitises some melanoma cells to killing by BH3 mimetic drugs
Gangoda, L., Schenk, R. L., Tai, L., Szeto, P., Cheung, J. G., Strasser, A., Lessène, G., Shackleton, M. J., & Herold, M. J. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04776-y · Cited by 3
Self-citationFakhri, B., & Danilov, A. V. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.01.009 · Cited by 3
Crystal structure of Mcl-1 in complex with compound 65
Toms, A. V., & Follows, B. (2019) · Worldwide Protein Data Bank · doi:10.2210/pdb6p3p/pdb · Cited by 3
Drug Discovery Beyond the Rule of Five
DeGoey, D. A., & Cox, P. B. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc258 · Cited by 3
CDK12/13 inhibitor, CTX-439, suppresses tumor growth and potentiates BCL-2 family blockadePreprint
Yamakawa, H., Khatab, R., Mizutani, A., Ebara, S., Hirayama, T., Tanaka, S., Tarumoto, Y., Sugiyama, M., Sugino, S., Takano, M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.20.706902 · Cited by 3
Zhai, L., Balachandran, A., Larkin, R., Seneviratne, J. A., Chung, S. A., Lalwani, A., Tsubota, S., Beck, D., Kadomatsu, K., Beckers, A., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115571 · Cited by 2
Bornkamm, G. W., Kelly, G. L., & Ross, A. M. (2025) · Current topics in microbiology and immunology · doi:10.1007/82_2025_301 · Cited by 2
Self-citationFRET two-hybrid assay-based target drug screening in living cells
Sun, B., Cao, G., Gan, T., Wang, Y., Hu, L., Hu, L., Chang, Y., Hu, M., Wang, X., & Chen, T. (2025) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2025.11.010 · Cited by 2
Dutta, K. K., Boro, M., Gomila, R. M., Frontera, A., Barcelo-Oliver, M., Gogoi, M., Verma, A. K., & Bhattacharyya, M. K. (2025) · Polyhedron · doi:10.1016/j.poly.2025.117932 · Cited by 2
When Targeted Therapy Falls Short: Unraveling Resistance Mechanisms in Chronic Lymphocytic Leukemia
Benrashid, S., & Woyach, J. A. (2026) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-026-00776-3 · Cited by 3
SMARCA4/2 loss reduces BCL-xL expression and confers a druggable MCL1 dependency in cancer
Jiang, J., Zhu, X., Fu, Z., Lao, M., Arabzadeh, A., Robert, F., Monast, A., Pilon, V., Pavlakis, K., Park, M., et al. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01350-z · Cited by 2
Wang, H., Shen, T., Yang, S., Zhou, X., Cao, P., Yu, H., He, K., Fu, M., Yu, H., Liu, X., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218446 · Cited by 2
Vey, N., Salamero, O., Bajel, A. R., Montesinos, P., Daver, N., Prébet, T., Legrand, O., Récher, C., Maillard, A., Hemon, A., et al. (2026) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2026.2699287 · Cited by 2
Self-citationTargeting protein–protein interactions in the BCL-2 family: opportunities for precision oncology
Malakar, V. K., Malakar, C. C., Mali, P. C., & Poddar, N. K. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04526-y · Cited by 2
Wang, J., He, Y., Yang, C., Luo, Q., & Wang, B. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2238900 · Cited by 2
Wang, H., Qi, Z., Lian, W., Ma, L., Wang, S., Liu, H., Jin, Y., Yang, H., Wang, J., & Cheng, M. (2024) · Physical Chemistry Chemical Physics · doi:10.1039/d4cp00576g · Cited by 2
Urabe, M., Ikezawa, K., Seiki, Y., Watsuji, K., Kawamoto, Y., Hirao, T., Kai, Y., Takada, R., Yamai, T., Mukai, K., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-73020-8 · Cited by 2
Hartman, M. L., Sztiller-Sikorska, M., & Czyż, M. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118183 · Cited by 2
Pignataro, C., Zoppoli, P., Cappelli, L. V., Yoffe, L., Moretti, M., Izzo, M., Mallia, S., Kayembe, C., Taylor, A., Petrillo, G., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015322 · Cited by 2
Modulation of Apoptosis Pathways in the Biology and Treatment of Multiple Myeloma
Bansal, R., Rakshit, S., Han, W., & Kumar, S. K. (2021) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2021.17.1.48 · Cited by 2
Therapeutics targeting BCL2 family proteins
Dai, H., Meng, X. W., Ye, K., Jia, J., & Kaufmann, S. H. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-814208-0.00007-5 · Cited by 2
BCL-W makes only minor contributions to MYC-driven lymphoma development
Diepstraten, S. T., Marca, J. E. L., Chang, C. W. T., Young, S., Strasser, A., & Kelly, G. L. (2023) · Oncogene · doi:10.1038/s41388-023-02804-5 · Cited by 2
Self-citationLi, Y., Song, Z., Xu, S., Xu, K., Xu, W., Xu, L., & Tian, F. (2025) · Phytotherapy Research · doi:10.1002/ptr.8492 · Cited by 2
The Servier oncology pipeline in 2017
Therasse, P., Perron, B., Novack, S. A., & Abastado, J. (2017) · Future Oncology · doi:10.2217/fon-2017-0129 · Cited by 2
On the Organization of a Drug Discovery Platform
Boutin, J. A., Nosjean, O., & Ferry, G. (2018) · InTech eBooks · doi:10.5772/intechopen.73170 · Cited by 2
Han, K. H., Kim, A., & Kim, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095134 · Cited by 2
MCL-1 Inhibitor S63845 Distinctively Affects Intramedullary and Extramedullary Hematopoiesis
Zhang, H., Li, F., Yang, M., Zhang, W., He, M. T., Xu, H., Wang, C., Zhang, Y., Wang, W., Gao, Y., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041085 · Cited by 3
Ohtsu, A., Arai, S., Sawada, T., Kato, M., Maeno, Y., Miyazawa, Y., Fujizuka, Y., Sekine, Y., Koike, H., Matsui, H., et al. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.08.083 · Cited by 2
EXABS-147-AML How Do We Overcome Resistance to Venetoclax
Saxena, K., Carter, B. Z., & Konopleva, M. Y. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/s2152-2650(22)00660-7 · Cited by 2
Fraser, C. S., Presser, A. G., Sanchorawala, V., Sarosiek, S., & Sarosiek, K. A. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/542159 · Cited by 2
Incorporating Precision BH3 Warheads Into the Offensive Against Acute Myeloid Leukemia
Savona, M. R., & Wei, A. H. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00400 · Cited by 2
Self-citationDeliu, Z., Shergill, A. P., Meier, A., Myint, P. T., Khan, S. N., Khosla, P. G., & Feldman, L. E. (2020) · Wiley eBooks · doi:10.1002/9781119432487.ch4 · Cited by 2
Gilmore, A. P. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734655745.793566256 · Cited by 2
Molecular control of the lymphocyte death timerPreprint
Ruhle, M., Thomas, E. A., Dann, E., Gottscheber, N., Teh, C. E., Gray, D. H. D., Dowling, M. R., Heinzel, S., & Hodgkin, P. D. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.25.563681 · Cited by 2
Exploring the Role of PROTACs for the Treatment of Breast Cancer
Pannu, A. S., Goyal, R. K., & Goswami, S. (2024) · Springer eBooks · doi:10.1007/978-981-97-5077-1_12 · Cited by 1
Zhang, Y., Wang, Q., Li, W., Li, Y., Li, Y., Liu, Z., Zhou, H., Luo, A., Chen, C., & Li, B. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102513 · Cited by 1
Cell Death Pathways: Intricate Connections and Disease Implications
Halder, S., & Jana, K. (2024) · Springer eBooks · doi:10.1007/978-981-97-7905-5_1 · Cited by 1
Gigaxonin Potentiates Antiviral Innate Immune Responses by Targeting cGAS and TREX1
Ji, B., Wang, J., Tu, Y., Zhang, S., Wei, Y., He, Y., Zhang, B., Zhao, Q., Hu, H., & Liu, Y. (2025) · Advanced Science · doi:10.1002/advs.202507146 · Cited by 1
Ghasemzadeh, M., Heidari, N., Naghinezhad, J., Ghasemzadeh, A., & Hosseini, E. (2025) · Cancer Medicine · doi:10.1002/cam4.71270 · Cited by 1
Critical Role of RPS4X in Modulating SCF Complex Formation and Cell Survival
Ryu, S., Kim, M. J., Bando, S., Tanaka, Y., Mukai, R., Ishihara, Y., Tominaga, T., & Ohshima, T. (2025) · Biomolecules · doi:10.3390/biom15101350 · Cited by 1
Sun, M., Li, L., Fu, R., Yang, Q., Chen, W., Yi, S., Gao, H., Gao, H., & Dong, N. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.112333 · Cited by 1
Liang, B. (2026) · Clinical bioenergetics · doi:10.3390/clinbioenerg2020009 · Cited by 1
The NLRP3 inflammasome at the crossroads of innate immune signaling and cell death
Xiao, N., Lu, Z., Cooper, D. K., & Chen, J. (2026) · Cellular and Molecular Immunology · doi:10.1038/s41423-026-01463-2 · Cited by 2
Murphy, J., & Rani, S. (2024) · Arrow - TU Dublin (Technological University Dublin) · doi:10.21427/p04v-pf26 · Cited by 1
Development of molecular intervention strategies for B-cell lymphoma
Zhou, W., & Chen, W. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2021.1856652 · Cited by 1
Calaspargase-Pegol-Mknl Combined with BCL-2 and MCL-1 Inhibition for Acute Myeloid Leukemia
Bollino, D. R., Ma, X., Tighe, K. M., Casildo, A., Richard, K., Passaniti, A., Carter‐Cooper, B., Strovel, E. T., & Emadi, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252313091 · Cited by 1
Adjumain, S., Daniel, P. M., Sun, C. X., Bradshaw, G., Chew, N. J., Tsui, V., Lee, H., Loi, M., Zhukova, N., Habarakada, D., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.184601 · Cited by 1
A Human Model of Oligodendrocyte Development Shows MCL ‐1 Influences Oligodendrocyte Morphogenesis
Gil, M., Hanna, M. R., & Gama, V. (2025) · Glia · doi:10.1002/glia.70128 · Cited by 1
Zhou, X., Zhu, M., Jiang, C., Ma, X., & Li, F. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109449 · Cited by 1
Cheng, J., Wang, H., Zhang, Y., & Liu, G. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117802 · Cited by 1
Diepstraten, S. T., Deng, Y., Potts, M. A., Heidersbach, A. J., Koenig, C., Dorighi, K. M., Tai, L., Kueh, A. J., Whelan, L., Chang, C. W. T., et al. (2026) · Science Advances · doi:10.1126/sciadv.aec0722 · Cited by 1
Self-citationSensitivity and Resistance to BH3 Mimetics in Cancer Therapy
Floros, K. V., Faber, A. C., & Harada, H. (2018) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-67932-7_7 · Cited by 1
No social distancing in the immune system
Miller, J. F. A. P. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20210646 · Cited by 1
A gyógyszerkutatás új irányzatai: hatékonyság és biztonságosság
Kotschy, A. (2021) · Scientia et Securitas · doi:10.1556/112.2021.00028 · Cited by 1
Self-citationCancer therapies: Caveats, concerns, and momentum
Anisman, H., & Kusnecov, A. W. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91904-3.00001-x · Cited by 1
Paulson, J. R., Luedtke, R. L., Suydam, S., Obi, D., & Xie, L. (2022) · International Journal of Biochemistry Research & Review · doi:10.9734/ijbcrr/2022/v31i630329 · Cited by 1
Modulation of Autophagy and Apoptosis in Leukemia
Torre, L. D., Beato, A., Capone, V., Carannante, D., Verrilli, G., Favale, G., Taherigorji, H., Naseer, M., Altucci, L., Benedetti, R., et al. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00039-1 · Cited by 1
Ye, K., Ni, J., Liu, D., Yang, S., Li, Y., Chen, M., Shah, F. A., Chen, H., Ji, W., Zheng, Y., et al. (2024) · Journal of Pineal Research · doi:10.1111/jpi.12943 · Cited by 1
Pioneering the Battle Against Breast Cancer: The Promise of New Bcl-2 Family
Boroujeni, A. F., & Ateş‐Alagöz, Z. (2024) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/0118715206320224240910054728 · Cited by 1
Dutta, R. P., Thibaud, S., Leshchenko, V. V., Ram, M., Melnekoff, D. T., Bhalla, S., Restrepo, P., Gupta, V. A., Barwick, B. G., Newman, S., et al. (2024) · Blood Neoplasia · doi:10.1016/j.bneo.2024.100049 · Cited by 1
Bio-mimetic strategies to re-activate apoptotic cell death for cancer treatments
Venerando, A., Lovison, D., & Marco, R. D. (2024) · Exploration of Drug Science · doi:10.37349/eds.2024.00074 · Cited by 1
Li, K., Ge, X., Liu, W., Huang, L., Lv, X., Tang, Y., He, Z. N. T., Yang, Y., Chen, M., Zeng, J., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062727 · Cited by 1
PTCH1 pathway network model in diffuse-type gastric cancer and epithelial mesenchymal transition
Tanabe, S., Aoyagi, K., Yokozaki, H., & Sasaki, H. (2018) · Journal of Stem Cell Research and Medicine · doi:10.15761/jscrm.1000128 · Cited by 1
Elucidating therapeutic molecular targets in premenopausal Asian women with recurrent breast cancers
Yap, Y. S., Singh, A., Lim, J. H. C., Ahn, J., Jung, K. H., Kim, J., Dent, R. A., Ng, R. C.-H., Kim, S.-B., & Chiang, D. Y. (2018) · European Journal of Cancer · doi:10.1016/s0959-8049(18)30653-1 · Cited by 1
Grundy, M. A., Al‐Kaisi, F., Cull, J., Williams, C. D., Smith, D., & Seedhouse, C. (2020) · eJHaem · doi:10.1002/jha2.133 · Cited by 1
Burger, R., Otte, A., Brdon, J., Peipp, M., & Gramatzki, M. (2021) · Haematologica · doi:10.3324/haematol.2020.276865 · Cited by 1
Ebrahimi, E., Shabestari, R. M., Bashash, D., & Safa, M. (2022) · Molecular Biology Reports · doi:10.1007/s11033-021-07021-5 · Cited by 1
AMG176, an MCL-1 inhibitor, is active in pre-clinical models of aggressive B-cell lymphomas
Torka, P., Russell, T., Mavis, C. K., Gu, J. J., Ghione, P., Barth, M. J., & Hernandez‐Ilizaliturri, F. J. (2023) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2200876 · Cited by 1
Metadata
- Authors
- Kotschy, A., Szlavik, Z., Murray, J., Davidson, J., Maragno, A. L., Le Toumelin-Braizat, G., Chanrion, M., Kelly, G. L., Gong, J.-N., Moujalled, D. M., Bruno, A., Csekei, M., Paczal, A., Szabo, Z. B., Sipos, S., Radics, G., Proszenyak, A., Balint, B., Ondi, L., Blasko, G., Robertson, A., Surgenor, A., Dokurno, P., Chen, I., Matassova, N., Smith, J., Pedder, C., Graham, C., Studeny, A., Lysiak-Auvity, G., Girard, A.-M., Gravé, F., Segal, D., Riffkin, C. D., Pomilio, G., Galbraith, L. C. A., Aubrey, B. J., Brennan, M. S., Herold, M. J., Chang, C., Guasconi, G., Cauquil, N., Melchiore, F., Guigal-Stephan, N., Lockhart, B., Colland, F., Hickman, J. A., Roberts, A. W., Huang, D. C. S., Wei, A. H., Strasser, A., Lessene, G., & Geneste, O.
- Affiliations
- Vernalis (R&D) Limited (United Kingdom) (GB)
- Institut de Recherches Internationales Servier (France) (FR)
- The University of Melbourne (AU)
- Monash University (AU)
- The Royal Melbourne Hospital (AU)
- The Alfred Hospital (AU)
- Corresponding author
- Geneste, Olivier
- ORCID
- Kotschy, András
- Murray, James
- Davidson, James
- Kelly, Gemma L.
- Moujalled, Donia M.
- Surgenor, Allan
- Dokurno, Pawel
- Chen, Ijen
- Matassova, Natalia
- Graham, Christopher
- Girard, Anne-Marie
- Segal, David
- Riffkin, Chris D.
- Galbraith, Laura C. A.
- Aubrey, Brandon J.
- Brennan, Margs S.
- Herold, Marco J.
- Chang, Catherine
- Melchiore, Fabien
- Colland, Frédéric
- Hickman, John A.
- Roberts, Andrew W.
- Huang, David C. S.
- Wei, Andrew H.
- Strasser, Andreas
- Venue
- Nature
- Published
- 2016-10
- Volume
- 538
- Issue
- 7626
- Pages
- 477-482
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2534349779
- Semantic Scholar
- 804d41f048a7386a3e6b3fcd1589511de3fabcd4
- Cited by
- 1,047
- References
- 52
- Citations by year
- 2026: 63 · 2025: 87 · 2024: 75 · 2023: 100 · 2022: 99 · 2021: 133 · 2020: 152 · 2019: 123 · 2018: 120 · 2017: 83 · 2016: 8
- FWCI
- 48.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- S63845, BH3-binding groove, apoptosis, mitochondrial apoptosis, multiple myeloma, leukemia, lymphoma, solid tumors, antitumour activity, drug safety, combination therapy
- MeSH terms
- Animals, Antineoplastic Agents, Female, Humans, Leukemia, Lymphoma, Male, Models, Biological, Models, Molecular, Multiple Myeloma, Neoplasms, Pyrimidines, Thiophenes, Apoptosis, Xenograft Model Antitumor Assays, Cell Line, Tumor, bcl-2 Homologous Antagonist-Killer Protein, bcl-2-Associated X Protein, Mice, Myeloid Cell Leukemia Sequence 1 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
